

# Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-InsulinProducing Cells Expression"

Jorge F.A. Model<sup>1</sup>

<sup>1</sup> Universidade Federal do Rio Grande do Sul

Potential competing interests: No potential competing interests to declare.

The article "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression" is very interesting. The proposed treatment of patients with type 1 diabetes (DM1) recently diagnosed with GLP-1 analogues together with insulin has some theoretical support, although points still need to be clarified.

In section "Comment 1" the authors suggest that GLP-1 agonists like semaglutide may discourage the release of anti-GAD antibodies, using a meta-analysis as the source of this information. I believe this is an indirect quote, as this article did not evaluate the anti-GAD antibodies outcome.

Another important aspect that supports the authors' hypothesis is the ability of liver cells to reprogramming into insulin-producing cells. This characteristic is very interesting and if it is possible to use it in regenerative medicine approaches, it could be extremely important for the treatment of DM1. However, although there is still some controversy over this issue, the most recent evidence indicates that human hepatocytes do not express the GLP-1 receptor. I believe this point is too important not to be discussed by the authors.